J&J $25 Million Antitrust Deal on Remicade Gets First Court Nod

Pension funds leading antitrust litigation against Johnson & Johnson unit Janssen Biotech Inc. won preliminary approval from a federal judge in Philadelphia for a $25 million settlement of allegations that the company schemed to delay generic versions of the anti-inflammatory drug Remicade.

Judge Karen S. Marston signed off tentatively Tuesday on the agreement, which would resolve class action claims brought in the US District Court for the Eastern District of Pennsylvania on behalf of end payers like union and municipal health plans. She said the terms of the deal appeared fair and adequate.

“Given the risks (and costs) associated with ...